Patient-Centered Home Cancer Screening Attitudes During COVID-19 Pandemic

Khoury, Christelle El; Haro, Elizabeth K.; Alves, Martha; O'Dwyer, Marie Claire; Meixner, Kate; Albiac, Laura Crespo; Capizzano, Juana Nicoll; Ramakrishnan, Manasi; Salada, Cullen; Gorin, Sherri Sheinfeld; Jimbo, Masahito; Sen, Ananda; Harper, Diane M.

doi:10.17294/2330-0698.1835

Cited by 7 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The introduction of peripheral blood CRC screening has a potentially major impact on public health as well. For example, the Coronavirus Disease 2019 (COVID-19) pandemic has caused global changes in the delivery of healthcare services since 2019, including both outpatient community-based services and inpatient hospital-admission services [ 34 ]. During the COVID-19 pandemic, an accurate non-invasive CRC screening test could be an alternative to colonoscopy to reduce the risk of the transmission of infectious diseases and to relieve the workload in healthcare sectors [ 35 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

Plasma Circulating mRNA Profile for the Non-Invasive Diagnosis of Colorectal Cancer Using NanoString Technologies

Tsang,

Pei,

Wong

et al. 2024

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most prevalent cancers and the second leading cause of cancer deaths in developed countries. Early CRC may have no symptoms and symptoms usually appear with more advanced diseases. Regular screening can identify people who are at increased risk of CRC in order to offer earlier treatment. A cost-effective non-invasive platform for the screening and monitoring of CRC patients allows early detection and appropriate treatment of the disease, and the timely application of adjuvant therapy after surgical operation is needed. In this study, a cohort of 71 plasma samples that include 48 colonoscopy- and histopathology-confirmed CRC patients with TNM stages I to IV were recruited between 2017 and 2019. Plasma mRNA profiling was performed in CRC patients using NanoString nCounter. Normalized data were analyzed using a Mann–Whitney U test to determine statistically significant differences between samples from CRC patients and healthy subjects. A multiple-group comparison of clinical phenotypes was performed using the Kruskal–Wallis H test for statistically significant differences between multiple groups. Among the 27 selected circulating mRNA markers, all of them were found to be overexpressed (gene expression fold change > 2) in the plasma of patients from two or more CRC stages. In conclusion, NanoString-based targeted plasma CRC-associated mRNAs circulating the marker panel that can significantly distinguish CRC patients from a healthy population were developed for the non-invasive diagnosis of CRC using peripheral blood samples.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma Circulating mRNA Profile for the Non-Invasive Diagnosis of Colorectal Cancer Using NanoString Technologies

Tsang,

Pei,

Wong

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…It is well established that CRC screening, as recommended by the USPSTF ( Force et al, 2016 ; Force et al, 2021 ) can be completed by any of six available tests, three of which are home based: FOBT, FIT, and multitarget stool DNA (FIT-DNA, Cologuard). Most recently, the American Cancer Society (ACS) and the USPSTF have recommended primary HPV testing for women 25/30–65 years for cervical cancer screening ( Fontham et al, 2020 ; Curry et al, 2018 ) as the test that provides the most benefit for the least harm which can also be an at-home test, a well-accepted option ( Maver and Poljak, 2020 ; Kim et al, 2018 ; El Khoury et al, 2021 ). Nevertheless, our data show that of those women who only choose one cancer to screen for, cervical cancer will be almost five times more likely to be the screen chosen.…”

Section: Discussionmentioning

confidence: 99%

“…Both cervical cancer and CRC generally do not have symptoms until a very late stage when cure is not possible ( World Health Organization, 2017 ), making early screening, even self-screening ( El Khoury et al, 2021 ; Bakr et al, 2020 ; Jaklevic, 2020 ), a critical health imperative.…”

Section: Introductionmentioning

confidence: 99%

US women screen at low rates for both cervical and colorectal cancers than a single cancer: a cross-sectional population-based observational study

Harper

Plegue

Jimbo

et al. 2022

eLife

Self Cite

View full text Add to dashboard Cite

Background:Using screen counts, women 50–64 years old have lower cancer screening rates for cervical and colorectal cancers (CRC) than all other age ranges. This paper aims to present woman-centric cervical cancer and CRC screenings to determine the predictor of being up-to-date for both.Methods:We used the Behavioral Risk Factor Surveillance System (BRFSS), an annual survey to guide health policy in the United States, to explore the up-to-date status of dual cervical cancer and CRC screening for women 50–64 years old. We categorized women into four mutually exclusive categories: up-to-date for dual-screening, each single screen, or neither screen. We used multinomial multivariate regression modeling to evaluate the predictors of each category.Results:Among women ages 50–64 years old, dual-screening was reported for 58.2% (57.1–59.4), cervical cancer screening alone (27.1% (26.0–28.2)), CRC screening alone (5.4% (4.9–5.9)), and neither screen (9.3% (8.7–9.9)). Age, race, education, income, and chronic health conditions were significantly associated with dual-screening compared to neither screen. Hispanic women compared to non-Hispanic White women were more likely to be up-to-date with cervical cancer screening than dual-screening (adjusted odds ratio [aOR] = 1.39 (1.10, 1.77)). Compared to younger women, those 60–64 years are significantly more likely to be up-to-date with CRC screening than dual-screening (aOR = 1.75 (1.30, 2.35)).Conclusions:Screening received by each woman shows a much lower rate of dual-screening than prior single cancer screening rates. Addressing dual-screening strategies rather than single cancer screening programs for women 50–64 years may increase both cancer screening rates.Funding:This work was supported by NIH through the Michigan Institute for Clinical and61 Health Research UL1TR002240 and by NCI through The University of Michigan Rogel Cancer62 Center P30CA046592 grants.

show abstract

HPV self-sampling among women in the United States: preferences for implementation

Garg,

Galvin,

Griner

et al. 2023

Cancer Causes Control

View full text Add to dashboard Cite

Patient-Centered Home Cancer Screening Attitudes During COVID-19 Pandemic

Cited by 7 publications

References 9 publications

Plasma Circulating mRNA Profile for the Non-Invasive Diagnosis of Colorectal Cancer Using NanoString Technologies

Plasma Circulating mRNA Profile for the Non-Invasive Diagnosis of Colorectal Cancer Using NanoString Technologies

US women screen at low rates for both cervical and colorectal cancers than a single cancer: a cross-sectional population-based observational study

HPV self-sampling among women in the United States: preferences for implementation

Contact Info

Product

Resources

About